The Efficacy and Safety of Apatinib in Advanced Synovial Sarcoma: A Case Series of Twenty-One Patients in One Single Institution.
apatinib
efficacy
safety
synovial sarcoma
targeted therapy
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2020
2020
Historique:
received:
17
03
2020
accepted:
11
06
2020
entrez:
17
7
2020
pubmed:
17
7
2020
medline:
17
7
2020
Statut:
epublish
Résumé
Synovial sarcoma (SS) is a highly aggressive soft-tissue sarcoma (STS) with poor prognosis. Tyrosine kinase inhibitor (TKI) has shown a promising impact on advanced STS patients. This study aimed to evaluate the efficacy and safety of apatinib, an oral multi-TKI, which especially inhibited vascular endothelial growth factor receptor, as second-line therapy for patients with advanced SS. This retrospective analysis included 21 advanced SS patients, who had a poor response to anthracycline-based chemotherapy alone or combined with ifosfamide at least one cycle. All the patients received an apatinib containing regimen between May 2016 and October 2019 in our institution. Apatinib 500-750 mg (250 mg for patients younger than 10) was given daily. Tumor responses were assessed by response evaluation criteria in solid tumors. Survival analysis was performed by the Kaplan-Meier test, and a safety profile was recorded. The median follow-up was 15.2 months (95% CI, 12.2-NE). Nine (42.9%) patients had partial response (PR), and eight (38.1%) had stable disease. The median progression-free survival (PFS) was 13.1 months (95% CI, 6.7-NE). The 6- and 12-month PFS rates were 76.2% (95% CI, 60.0-96.8) and 55.4% (95% CI, 37.3-82.3), respectively. Additionally, the median overall survival (OS) was 15.5 months (95% CI, 10.7-NE). The 6- and 12-month OS rates were 81.0% (95% CI, 65.8, 99.6) and 64.9% (95% CI, 46.9-90.0), respectively. Moreover, the objective response rate was 42.9% (9/21) for advanced SS patients. The disease control rate was 81.0% (17/21). For the nine patients with the best response of PR, the median duration of response was 7.7 months. Apatinib was proved to be a potential second-line treatment option for advanced SS patients with chemo-resistance. Apatinib showed promising efficacy and acceptable safety profile in advanced SS, with considerable OS and particularly PFS. Indeed, further multicenter studies with a longer follow-up time are needed to fully determine the clinical application of apatinib in advanced SS.
Sections du résumé
BACKGROUND
BACKGROUND
Synovial sarcoma (SS) is a highly aggressive soft-tissue sarcoma (STS) with poor prognosis. Tyrosine kinase inhibitor (TKI) has shown a promising impact on advanced STS patients. This study aimed to evaluate the efficacy and safety of apatinib, an oral multi-TKI, which especially inhibited vascular endothelial growth factor receptor, as second-line therapy for patients with advanced SS.
PATIENTS AND METHODS
METHODS
This retrospective analysis included 21 advanced SS patients, who had a poor response to anthracycline-based chemotherapy alone or combined with ifosfamide at least one cycle. All the patients received an apatinib containing regimen between May 2016 and October 2019 in our institution. Apatinib 500-750 mg (250 mg for patients younger than 10) was given daily. Tumor responses were assessed by response evaluation criteria in solid tumors. Survival analysis was performed by the Kaplan-Meier test, and a safety profile was recorded.
RESULTS
RESULTS
The median follow-up was 15.2 months (95% CI, 12.2-NE). Nine (42.9%) patients had partial response (PR), and eight (38.1%) had stable disease. The median progression-free survival (PFS) was 13.1 months (95% CI, 6.7-NE). The 6- and 12-month PFS rates were 76.2% (95% CI, 60.0-96.8) and 55.4% (95% CI, 37.3-82.3), respectively. Additionally, the median overall survival (OS) was 15.5 months (95% CI, 10.7-NE). The 6- and 12-month OS rates were 81.0% (95% CI, 65.8, 99.6) and 64.9% (95% CI, 46.9-90.0), respectively. Moreover, the objective response rate was 42.9% (9/21) for advanced SS patients. The disease control rate was 81.0% (17/21). For the nine patients with the best response of PR, the median duration of response was 7.7 months.
CONCLUSION
CONCLUSIONS
Apatinib was proved to be a potential second-line treatment option for advanced SS patients with chemo-resistance. Apatinib showed promising efficacy and acceptable safety profile in advanced SS, with considerable OS and particularly PFS. Indeed, further multicenter studies with a longer follow-up time are needed to fully determine the clinical application of apatinib in advanced SS.
Identifiants
pubmed: 32669874
doi: 10.2147/CMAR.S254296
pii: 254296
pmc: PMC7335867
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5255-5264Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2020 Wang et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Cancer. 2009 Jul 1;115(13):2988-98
pubmed: 19452538
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Eur J Cancer. 2010 Jan;46(1):72-83
pubmed: 19853437
J Clin Oncol. 2016 May 1;34(13):1448-54
pubmed: 26884585
BMC Cancer. 2018 Apr 6;18(1):396
pubmed: 29625604
BMC Cancer. 2015 Mar 19;15:154
pubmed: 25885855
Lancet Oncol. 2017 Aug;18(8):1089-1103
pubmed: 28651927
Cancer. 2017 Jun 15;123(12):2294-2302
pubmed: 28295221
Medicine (Baltimore). 2019 Dec;98(51):e18382
pubmed: 31861000
J Clin Oncol. 2018 Jan 10;36(2):180-187
pubmed: 29220290
Cancer Sci. 2011 Jul;102(7):1374-80
pubmed: 21443688
Oncogene. 2001 Sep 10;20(40):5755-62
pubmed: 11607825
BMJ Case Rep. 2015 Sep 02;2015:
pubmed: 26336188
Acta Oncol. 2017 Dec;56(12):1769-1775
pubmed: 28723233
Cancer Biol Ther. 2018 Mar 4;19(3):198-204
pubmed: 29261005
Eur J Surg Oncol. 2017 Sep;43(9):1733-1739
pubmed: 28579008
Target Oncol. 2018 Aug;13(4):417-422
pubmed: 29931504
Cancer. 2016 May 1;122(9):1408-16
pubmed: 26970174
J Clin Oncol. 2009 Jul 1;27(19):3133-40
pubmed: 19451436
J Cancer. 2017 Jul 1;8(10):1759-1768
pubmed: 28819372
J Clin Oncol. 2009 Jul 1;27(19):3126-32
pubmed: 19451427
Lancet Oncol. 2016 Dec;17(12):1732-1742
pubmed: 27751846
Crit Rev Oncol Hematol. 2013 Oct;88(1):187-97
pubmed: 23561333
Eur J Cancer. 2018 Aug;99:28-36
pubmed: 29902612
Oncology. 2019;96(2):59-69
pubmed: 30336470
Ann Oncol. 2015 Mar;26(3):567-72
pubmed: 25488687
Lancet. 2012 May 19;379(9829):1879-86
pubmed: 22595799
Lancet Oncol. 2015 Apr;16(4):406-16
pubmed: 25795406
Cancers (Basel). 2018 Nov 01;10(11):
pubmed: 30388821
Cancer. 2004 Aug 1;101(3):627-34
pubmed: 15274077
Cancer Res. 2010 Oct 15;70(20):7981-91
pubmed: 20876799
Expert Opin Emerg Drugs. 2019 Mar;24(1):43-53
pubmed: 30841761
J Natl Compr Canc Netw. 2016 Jun;14(6):758-86
pubmed: 27283169
BMC Cancer. 2015 Mar 14;15:127
pubmed: 25884155
J Natl Compr Canc Netw. 2018 May;16(5):536-563
pubmed: 29752328